Drug Patents owned by Covis

1. Drug name - ALVESCO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8371292 COVIS Use of ciclesonide for the treatment of respiratory diseases
Feb, 2028

(5 years from now)

Drugs and Companies using CICLESONIDE ingredient

Market Authorisation Date: 10 January, 2008

Treatment: Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. patent claims method for treating a respiratory disease in a child

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
0.08MG/INH AEROSOL, METERED;INHALATION Prescription
0.16MG/INH AEROSOL, METERED;INHALATION Prescription

2. Drug name - FERAHEME

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6599498 COVIS Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohdrate derivatives
Jun, 2023

(6 months from now)

Drugs and Companies using FERUMOXYTOL ingredient

Market Authorisation Date: 30 June, 2009

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 510MG IRON/17ML (EQ 30MG IRON/ML) SOLUTION;INTRAVENOUS Prescription

3. Drug name - MAKENA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446441 COVIS Prefilled syringe injector
Jan, 2026

(3 years from now)

US9533102 COVIS Prefilled syringe jet injector
Jan, 2026

(3 years from now)

US9180259 COVIS Prefilled syringe jet injector
Jan, 2026

(3 years from now)

US8562564 COVIS Prefilled syringe jet injector
Jan, 2026

(3 years from now)

US9629959 COVIS Prefilled syringe jet injector
Jan, 2026

(3 years from now)

US8021335 COVIS Prefilled syringe jet injector
Oct, 2026

(3 years from now)

US11446440 COVIS Needle assisted injection device having reduced trigger force
Aug, 2031

(8 years from now)

US9789257 COVIS Needle assisted injection device having reduced trigger force
Feb, 2034

(11 years from now)

US11154562 COVIS Methods of reducing risk of preterm birth
May, 2036

(13 years from now)

US11304962 COVIS Methods of reducing risk of preterm birth
May, 2036

(13 years from now)

US9844558 COVIS Methods of reducing risk of preterm birth
May, 2036

(13 years from now)

US10471075 COVIS Methods of reducing risk of preterm birth
May, 2036

(13 years from now)

Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient

Market Authorisation Date: 03 February, 2011

Treatment: Reducing the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth

Dosage: SOLUTION;INTRAMUSCULAR; SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
1250MG/5ML (250MG/ML) SOLUTION;INTRAMUSCULAR Prescription
250MG/ML (250MG/ML) SOLUTION;INTRAMUSCULAR Prescription
275MG/1.1ML (250MG/ML) SOLUTION;SUBCUTANEOUS Prescription

4. Drug name - OMNARIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8371292 COVIS Use of ciclesonide for the treatment of respiratory diseases
Feb, 2028

(5 years from now)

Drugs and Companies using CICLESONIDE ingredient

Market Authorisation Date: 20 October, 2006

Treatment: Treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. treatment of nasal symptoms associated w perennial allergic rhinitis in adults and adolescents 12 years of age and older

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.05MG/SPRAY SPRAY, METERED;NASAL Prescription

5. Drug name - ZETONNA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8371292 COVIS Use of ciclesonide for the treatment of respiratory diseases
Feb, 2028

(5 years from now)

Drugs and Companies using CICLESONIDE ingredient

Market Authorisation Date: 20 January, 2012

Treatment: Treatment of symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older. patent claims methods for treating a respiratory disease in a child

Dosage: AEROSOL, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.037MG/INH AEROSOL, METERED;NASAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in